Joint project to drive the development of a new topical treatment for Atopic Dermatitis

Important results from the project

The purpose of the project and its consortium was to drive and support the development of TIR-C, a new medication for atopic dermatitis. All the objectives set for the project have been achieved, except for the GLP validation sub-goal within WP2. In summary, it can be concluded that the project, largely driven by the results of the efficacy study, has surpassed the overall main goal by a significant margin.

Expected long term effects

The outcome of this project is expected to enable the next step in the development of TIR-C. Specifically, it instills confidence in the team to proceed towards clinical trials. The collaboration established during this project is anticipated to deepen in the upcoming period. Additionally, further work will be carried out to facilitate GLP validation of the developed analytical methods.

Approach and implementation

It can be noted that the original timeline was not achieved, due to unexpected delays within WP1 and complexity in the development of bioanalytical methods within WP2. Additionally, it can be observed that there were additional costs incurred in relation to the budget, primarily due to significant changes in the Euro exchange rate against the Krona. Future projects should take such contingencies into account to provide additional assurance in the work plan.